Matrine Inhibits CNS Autoimmunity Through an IFN-β-Dependent Mechanism

Yao-Juan Chu,Wen-Di Ma,Rodolfo Thome,Jie-Dan Ping,Fang-Zhou Liu,Meng-Ru Wang,Ming-Liang Zhang,Guangxian Zhang,Lin Zhu

DOI: https://doi.org/10.3389/fimmu.2020.569530

IF: 7.3

2020-09-25

Frontiers in Immunology

Abstract:Matrine (MAT), a quinolizidine alkaloid component derived from the root of <i>Sophora flavescens</i>, suppresses experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), by inducing the production of immunomodulatory molecules, e.g., IL-10. In an effort to find the upstream pathway(s) of the mechanism underlying these effects, we have tested certain upregulated immunomodulatory molecules. Among them, we found increased levels of IL-27 and IFN-β, one of the first-line MS therapies. Indeed, while low levels of IFN-β production in sera and type I interferon receptor (IFNAR1) expression in spinal cord of saline-treated control EAE mice were detected, they were significantly increased after MAT treatment. Increased numbers of CD11b⁺IFN-β⁺ microglia/infiltrating macrophages were observed in the CNS of MAT-treated mice. The key role of IFN-β induction in the suppressive effect of MAT on EAE was further verified by administration of anti-IFN-β neutralizing antibody, which largely reversed the therapeutic effect of MAT. Further, we found that, while MAT treatment induced production of IL-27 and IL-10 by CNS microglia/macrophages, this effect was significantly reduced by IFN-β neutralizing antibody. Finally, the role of IFN-β in MAT-induced IL-27 and IL-10 production was further confirmed in human monocytes <i>in vitro</i>. Together, our study demonstrates that MAT exerts its therapeutic effect in EAE through an IFN-β/IL-27/IL-10 pathway, and is likely a novel, safe, low-cost, and effective therapy as an alternative to exogenous IFN-β for MS.

immunology